公开(公告)号：US20240245721A1

公开(公告)日：2024-07-25

申请号：US18558882

申请日：2022-05-05

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Kytai NGUYEN ,  Jon WEIDANZ ,  Serkan YAMAN ,  Harish RAMACHANDRAMOORTHY ,  Manoj Kumar SABNANI

IPC分类号： A61K35/17 ,  A61K9/16 ,  A61K39/00 ,  C07K14/725 ,  C07K16/32

CPC分类号： A61K35/17 ,  A61K9/1647 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464406 ,  C07K14/7051 ,  C07K16/32 ,  A61K2239/13 ,  A61K2239/29 ,  A61K2239/49 ,  A61K2239/55 ,  C07K2317/31 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03

摘要： Disclosed are chimeric antigen receptor (CAR) engineered T lymphocyte membrane coated nanoparticles (CAR-T MNP) compositions and methods of using the same for delivering therapeutics to a particular target.

公开(公告)号：US20240226163A1

公开(公告)日：2024-07-11

申请号：US18559009

申请日：2022-05-03

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Kevin BRAY ,  Frank DELFINO ,  David DILILLO

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464486 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/2809 ,  C07K16/30 ,  A61K2239/13 ,  A61K2239/28 ,  A61K2239/29 ,  C07K2317/31 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03

摘要： MAGE-A4, or Melanoma-Associated Antigen A4, is a cancer-testis antigen (CTA) on the X chromosome. The present disclosure provides MAGE-A4-specific chimeric antigen receptors, cells expressing such chimeric antigen receptors, and MAGE-A4 specific isolated antibodies. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present disclosure are capable of inhibiting the growth of tumors expressing MAGE-A4. The engineered cells of the present disclosure are useful for the treatment of diseases and disorders in which an upregulated or induced MAGE-A4-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the MAGE-A4-specific chimeric antigen receptors of the present disclosure are useful for the treatment of various cancers.

公开(公告)号：US20240226151A9

公开(公告)日：2024-07-11

申请号：US18278495

申请日：2022-02-25

申请人： CRAGE MEDICAL CO., LIMITED

发明人： Zonghai LI ,  Zhimin SHI

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N9/22

CPC分类号： A61K35/17 ,  A61K39/4631 ,  A61P35/00 ,  C07K16/2851 ,  C12N9/22 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/55 ,  C07K2317/622 ,  C12N2310/20

摘要： An engineered immune cell for immunotherapy, which has a relatively high persistence and/or survival rate of transplantation in a host organism, and a preparation method therefor.

公开(公告)号：US20240216430A1

公开(公告)日：2024-07-04

申请号：US18521196

申请日：2023-11-28

申请人： ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

发明人： Zhe LI ,  Siler PANOWSKI ,  Barbra Johnson SASU ,  Bryan A. SMITH ,  Thomas John VAN BLARCOM ,  Tao SAI ,  Guoyun ZHU

IPC分类号： A61K35/17 ,  A61K39/00 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464438 ,  C07K16/2875 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/23 ,  A61K2239/29 ,  A61K2239/31 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

摘要： Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs.

公开(公告)号：US20240207313A1

公开(公告)日：2024-06-27

申请号：US18287556

申请日：2022-04-21

申请人： Imperial College Innovations Limited

发明人： Xiaoning Xu ,  Weiwei Ma

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/02 ,  C07K16/28 ,  C12N15/85

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61K45/06 ,  A61P35/02 ,  C07K16/2809 ,  C07K16/2863 ,  C12N15/85 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/48

摘要： The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-T-cell receptor (TCR) V-beta CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.

公开(公告)号：US20240207310A1

公开(公告)日：2024-06-27

申请号：US18286967

申请日：2022-04-15

申请人： Celgene Corporation

发明人： Julie Ann RYTLEWSKI ,  Gianfranco PITTARI

IPC分类号： A61K35/17 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/69 ,  A61K39/00 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/69 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  C07K16/2878 ,  C07K16/2896 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/38 ,  A61K2239/48

摘要： Provided herein are methods, compositions, and uses for treating subjects with diseases and conditions, such as those involving or associated with B cell maturation antigen (BCMA). In some aspects, the present disclosure relates to certain combination therapies that include administration of a cell therapy, such as a BCMA-targeted T cell therapy, in combination with immunomodulatory agents and other agents, such as dexamethasone, including for the treatment of subjects with multiple myeloma. In some embodiments, the multiple myeloma is a relapsed or refractory multiple myeloma.

公开(公告)号：US20240165161A1

公开(公告)日：2024-05-23

申请号：US18525534

申请日：2023-11-30

申请人： The Regents of the University of California ,  Northwestern University

发明人： Kole ROYBAL ,  Julie Garcia ,  Iowis Zhu ,  Jaehyuk Choi ,  Jay Daniels

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K14/82 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464412 ,  A61K39/46445 ,  A61K39/464462 ,  A61P35/00 ,  C07K14/4747 ,  C07K14/82 ,  C07K16/2803 ,  C12N5/0636 ,  A61K2239/13

摘要： The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NFAT, NF-κB and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.

公开(公告)号：US20240165160A1

公开(公告)日：2024-05-23

申请号：US18495531

申请日：2023-10-26

申请人： Kite Pharma, Inc.

发明人： Justin A. Budka ,  Justyna E. Kanska

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86 ,  G01N33/50

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464412 ,  A61P35/00 ,  C07K16/2803 ,  C12N5/0636 ,  C12N15/86 ,  G01N33/505 ,  A61K2239/13 ,  A61K2239/38 ,  A61K2239/48 ,  G01N2800/52

摘要： Provided herein are methods for preparing, producing, processing, culturing, isolating, of making cells suitable for immune or cell therapy, and for their use in cell therapy. Further provided are methods for treatment of a cancer patient with such cells.

公开(公告)号：US20240117063A1

公开(公告)日：2024-04-11

申请号：US18473965

申请日：2023-09-25

申请人： TeneoBio, Inc.

发明人： Nathan Trinklein ,  Katherine Harris ,  Nicole Allen ,  Karen Chang ,  Brian Avanzino

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2887 ,  A61K39/4631 ,  A61P35/00 ,  A61K2239/13 ,  C07K2317/565

摘要： Ani-CD20 antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD20.

公开(公告)号：US20240115606A1

公开(公告)日：2024-04-11

申请号：US18267231

申请日：2021-12-15

申请人： Universiteit Antwerpen

发明人： Astrid VAN DEN EYNDE ,  Evelien SMITS ,  Patrick PAUWELS ,  Julie JACOBS

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464429 ,  A61K39/46444 ,  A61P35/00 ,  C07K14/5434 ,  C07K14/5443 ,  C07K16/2875 ,  C12N5/0646 ,  A61K2239/13 ,  A61K2239/22 ,  A61K2239/50

摘要： The invention provides a natural killer (NK) cell engineered to express a chimeric antigen receptor (CAR), wherein the CAR comprises the extracellular domain of CD27 or a CD70-binding portion thereof, as well as compositions comprising the engineered NK cell, methods for producing the engineered NK cell, and therapeutic applications of the engineered NK cell, such as for treating neoplastic diseases.